{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T14:11:14Z","timestamp":1785247874337,"version":"3.55.0"},"reference-count":34,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2010,2,11]],"date-time":"2010-02-11T00:00:00Z","timestamp":1265846400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2010,4,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>BACKGROUND:<\/jats:title><jats:p>A study was undertaken to determine whether route (intraventricular vs intralumbar) of intracerebrospinal fluid (intra\u2010CSF) drug administration influences progression\u2010free survival in the treatment of patients with neoplastic meningitis, which occurs in 1% to 5% of patients with known cancer. Currently available treatment options result in modest responses, which is in part a reflection of obstacles to drug delivery into the leptomeningeal space.<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS:<\/jats:title><jats:p>One hundred patients with clinically and cytologically or radiographically documented neoplastic meningitis because of solid cancers received intra\u2010CSF liposomal cytarabine or methotrexate as specified in a randomized phase 4 trial. The 2 treatment arms were well balanced for demographic and tumor\u2010related characteristics of known prognostic importance, including age, performance status, tumor type, extent of systemic and other central nervous system (CNS) disease, prior CNS therapy, and concurrent systemic chemotherapy.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS:<\/jats:title><jats:p>One hundred patients were randomized and treated (52 with sustained\u2010release cytarabine, and 48 with methotrexate). Progression\u2010free survival (the primary study endpoint) was identical between the sustained\u2010release cytarabine and methotrexate treatment arms for all 100 patients (35 vs 37.5 days, <jats:italic>P<\/jats:italic> = .79). When progression\u2010free survival was examined as a function of route of chemotherapy administration (lumbar vs ventricular), there was no difference for patients treated with sustained\u2010release cytarabine (29 vs 43 days, <jats:italic>P<\/jats:italic> = .35). For patients treated with methotrexate, however, there was a statistically significant difference favoring patients receiving intraventricular therapy (19 vs 43 days, <jats:italic>P<\/jats:italic> = .048).<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS:<\/jats:title><jats:p>Site of intra\u2010CSF chemotherapy drug administration is clinically relevant with short half\u2010life drugs such as methotrexate. Cancer 2010. \u00a9 2010 American Cancer Society.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cncr.24921","type":"journal-article","created":{"date-parts":[[2010,2,11]],"date-time":"2010-02-11T10:46:30Z","timestamp":1265885190000},"page":"1947-1952","source":"Crossref","is-referenced-by-count":100,"title":["Route of intracerebrospinal fluid chemotherapy administration and efficacy of therapy in neoplastic meningitis"],"prefix":"10.1002","volume":"116","author":[{"given":"Michael J.","family":"Glantz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alixis","family":"Van Horn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Fisher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc C.","family":"Chamberlain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2010,4,6]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.01.131"},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1987.5.10.1655"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1993.11.3.561"},{"key":"e_1_2_7_5_2","first-page":"3394","article-title":"A randomized controlled trial comparing intrathecal sustained\u2010release cytarabine (Depo\u2010Cyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors","volume":"5","author":"Glantz MJ","year":"1999","journal-title":"Clin Cancer Res."},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.10.3110"},{"key":"e_1_2_7_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2004.08.012"},{"issue":"18","key":"e_1_2_7_8_2","first-page":"65S","article-title":"A randomized phase 3 of 4 study to determine benefit and safety of cytarabine liposome injection for treatment of neoplastic meningitis","volume":"24","author":"Shapiro WR","year":"2006","journal-title":"Proc ASCO."},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.1080\/07357900600815166"},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1005948722912"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1005996606073"},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.1215\/15228517-2007-059"},{"key":"e_1_2_7_13_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.06.053"},{"key":"e_1_2_7_14_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-05-2094"},{"key":"e_1_2_7_15_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21828"},{"key":"e_1_2_7_16_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.09.7311"},{"key":"e_1_2_7_17_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200544010-00001"},{"key":"e_1_2_7_18_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19950615)75:12<2919::AID-CNCR2820751220>3.0.CO;2-9"},{"key":"e_1_2_7_19_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.46.6.1674"},{"key":"e_1_2_7_20_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.50.2.438"},{"key":"e_1_2_7_21_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197310112891503"},{"key":"e_1_2_7_22_2","first-page":"703","article-title":"Clinical pharmacology of intrathecal methotrexate: I. Pharmacokinetics in nontoxic patients after lumbar injection","volume":"61","author":"Bleyer WA","year":"1977","journal-title":"Cancer Treat Rep."},{"key":"e_1_2_7_23_2","first-page":"1419","article-title":"Clinical pharmacology of intrathecal methotrexate: II. An improved dosage regimen derived from age\u2010related pharmacokinetics","volume":"61","author":"Bleyer WA","year":"1977","journal-title":"Cancer Treat Rep."},{"key":"e_1_2_7_24_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1993.11.11.2186"},{"key":"e_1_2_7_25_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197507242930402"},{"key":"e_1_2_7_26_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1990.00390130145023"},{"key":"e_1_2_7_27_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.35.9.1274"},{"key":"e_1_2_7_28_2","first-page":"172","article-title":"Complications associated with intraventricular chemotherapy in patients with leptomeningeal metastases","volume":"89","author":"Chamberlain MC","year":"1998","journal-title":"J Neurosurg."},{"key":"e_1_2_7_29_2","doi-asserted-by":"publisher","DOI":"10.1097\/00006123-200007000-00011"},{"key":"e_1_2_7_30_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11449"},{"key":"e_1_2_7_31_2","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.1974.00490320010002"},{"key":"e_1_2_7_32_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19820215)49:4<759::AID-CNCR2820490427>3.0.CO;2-7"},{"key":"e_1_2_7_33_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.42.6.1239"},{"key":"e_1_2_7_34_2","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/3.1.42"},{"key":"e_1_2_7_35_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19980215)82:4<733::AID-CNCR17>3.0.CO;2-Z"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.24921","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.24921","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T12:50:54Z","timestamp":1760273454000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.24921"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,4,6]]},"references-count":34,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2010,4,15]]}},"alternative-id":["10.1002\/cncr.24921"],"URL":"https:\/\/doi.org\/10.1002\/cncr.24921","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,4,6]]}}}